These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 10446490)

  • 61. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
    Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
    Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [The comparative evaluation of the efficacy of different therapeutic plans in acute nonlymphocytic leukemias].
    Volkova MA; Kaletin GI; Pirogova NA
    Ter Arkh; 1993; 65(7):18-23. PubMed ID: 8211772
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins.
    Candoni A; Michelutti A; Simeone E; Damiani D; Baccarani M; Fanin R
    Eur J Haematol; 2006 Oct; 77(4):293-9. PubMed ID: 16856922
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phase I-II study of aclacinomycin for a treatment of acute myeloid leukemia.
    Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Dorval T; Ribaud P
    Biomed Pharmacother; 1984; 38(7):328-31. PubMed ID: 6596962
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin.
    Seipelt G; Hofmann WK; Martin H; Wassmann B; Boehme A; Ottmann OG; Hoelzer D
    Ann Hematol; 1998; 76(3-4):145-51. PubMed ID: 9619732
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Do de novo acute myeloid leukemias with normal cytogenetics involve two main prognostic categories distinguished by the presence of erythroblastic and/or megakaryocytic dysplasia?
    Lemez P; Gáliková J; Haas T
    Neoplasma; 2000; 47(1):41-7. PubMed ID: 10870686
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
    Minakata D; Fujiwara S; Ito S; Mashima K; Umino K; Nakano H; Kawasaki Y; Sugimoto M; Yamasaki R; Yamamoto C; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
    Leuk Res; 2016 Mar; 42():82-7. PubMed ID: 26790727
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Role of daunorubicin in the induction therapy for adult acute myeloid leukemia.
    Usui N; Dobashi N; Kobayashi T; Yano S; Maki N; Asai O; Saito T; Yamaguchi Y; Watanabe H; Kato A; Ogihara A; Katori M; Nagamine M; Takei Y; Yamazaki H; Funakoshi S; Tajima N; Ogawa M; Kuraishi Y
    J Clin Oncol; 1998 Jun; 16(6):2086-92. PubMed ID: 9626208
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Progress in acute myelogenous leukemia.
    Gale RP
    Cancer Treat Rep; 1981; 65 Suppl 4():87-92. PubMed ID: 7049383
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat.
    Laszlo D; Agazzi A; Goldhirsch A; Cinieri S; Bertolini F; Rabascio C; Pruneri G; Calabrese L; Cocquio A; Martinelli G
    Eur J Haematol; 2004 Apr; 72(4):264-7. PubMed ID: 15089764
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The results of treatment with idarubicin in childhood acute nonlymphoblastic leukemia.
    Saşmaz I; Tanyeli A; Bayram I; Antmen B; Yilmaz L; Küçükosmanoğlu O; Kilinç Y
    Turk J Pediatr; 2004; 46(1):32-7. PubMed ID: 15074372
    [TBL] [Abstract][Full Text] [Related]  

  • 73. High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long-term follow-up of a prospective multicenter trial.
    Heil G; Mitrou PS; Hoelzer D; Freund M; Link H; Ehninger G; Steinke B; Ohl S; Wandt H; Fackler-Schwalbe E
    Ann Hematol; 1995 Nov; 71(5):219-25. PubMed ID: 7492624
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Aclacinomycin A and behenoyl ara-C combination chemotherapy for untreated acute non-lymphocytic leukemia].
    Sampi K; Honda T; Hayashi Y; Hattori M
    Gan To Kagaku Ryoho; 1983 Oct; 10(10):2211-6. PubMed ID: 6578705
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
    Kern W; Aul C; Maschmeyer G; Schönrock-Nabulsi R; Ludwig WD; Bartholomäus A; Bettelheim P; Wörmann B; Büchner T; Hiddemann W
    Leukemia; 1998 Jul; 12(7):1049-55. PubMed ID: 9665189
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Successful re-induction therapy for acute myelogenous leukemia with cytosine arabinoside and daunorubicin.
    Stein RS; Flexner JM
    Cancer Treat Rep; 1979; 63(11-12):2123-4. PubMed ID: 294309
    [No Abstract]   [Full Text] [Related]  

  • 77. [Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia].
    Malpas J; Mathé G; Hayat M
    Bull Cancer; 1974; 61(3):411-8. PubMed ID: 4533741
    [No Abstract]   [Full Text] [Related]  

  • 78. Prognostic factors in adult patients with acute leukemia.
    Arimori S; Nagao T
    Tokai J Exp Clin Med; 1983 Dec; 8(5-6):411-7. PubMed ID: 6242082
    [TBL] [Abstract][Full Text] [Related]  

  • 79. High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group.
    Lazarus HM; Vogler WR; Burns CP; Winton EF
    Cancer; 1989 Mar; 63(6):1055-9. PubMed ID: 2917307
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.
    Berman E; McBride M; Lin S; Menedez-Botet C; Tong W
    Leukemia; 1995 Oct; 9(10):1631-7. PubMed ID: 7564501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.